Dr. David S. Goldfarb, MD

Dr. Goldfarb practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Goldfarb's NPI, 1629018908, was assigned on June 7, 2006. Dr. Goldfarb graduated from Yale School of Medicine in 1981. Dr. Goldfarb holds New York license 154306.

Dr. Goldfarb's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Goldfarb's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Goldfarb is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Goldfarb to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldfarb practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Goldfarb's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Goldfarb is board certified in internal medicine by the American Board of Internal Medicine. Dr. Goldfarb is licensed in New York.

Dmand AI lists chronic kidney disease among the conditions Dr. Goldfarb treats.

CMS data shows 75 Medicare services from Dr. Goldfarb across 3 procedure codes in 2024, for 68 Medicare patients. Medicare paid $5,307 for them. Every service was in an office.

CMS counts 68 Medicare patients who saw Dr. Goldfarb in 2024. The largest group is 75 to 84, with 33 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Goldfarb's median patient age at 61, with 38% women.

In 2024, Dr. Goldfarb wrote 565 Medicare Part D claims for 93 patients. 76% of them were for generic drugs. CMS names the drug for 384 of them, across 11 drugs with 11 or more claims each, at $364,498 in total drug cost. In 2023, CMS named 354 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Goldfarb for performance year 2024, reported as part of a group. Dr. Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldfarb as offering telehealth.

Dmand AI links 287 papers to Dr. Goldfarb, published from 2003 to 2025. 2023 was the busiest year, with 13. The most frequent topics are Kidney Calculi, Renal Dialysis and Saccharomyces cerevisiae. Dr. Goldfarb has published most often in Am J Kidney Dis. Dr. Goldfarb's most frequent co-authors are John R. Asplin, MD, John C. Lieske, MD and Lama Nazzal, MD.

Dmand AI links Dr. Goldfarb to 14 clinical trials. 3 are still active or recruiting. Conditions studied include Cystinuria, Renal Aminoacidurias and Nephrolithiasis. NYU Langone Health sponsors the most, 7.

CMS Open Payments shows 195 general payments to Dr. Goldfarb from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Travere Therapeutics, Inc. paid the most, $71,044. It also lists 2 research payments totaling $4,000 in 2021.

Dmand AI lists 3 awards for Dr. Goldfarb, most recently Fellow, NKF in 2014.

Dr. Goldfarb graduated from Yale School of Medicine in 1981. Dr. Goldfarb is a member of ASN, AUA and NKF.

Dr. Goldfarb is in network with 17 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.